{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T05:24:09Z","timestamp":1740806649055,"version":"3.38.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.clinthera.2010.11.006","type":"journal-article","created":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T10:47:42Z","timestamp":1291114062000},"page":"2106-2115","source":"Crossref","is-referenced-by-count":6,"title":["Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers"],"prefix":"10.1016","volume":"32","author":[{"given":"Karisa Cristina Rodrigues","family":"Belotto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00e1dia Rezende Barbosa","family":"Raposo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline Siqueira","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wagner Farid","family":"Gattaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.11.006_bib1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems","volume":"347","author":"McCracken","year":"2002","journal-title":"N EnglJ Med."},{"key":"10.1016\/j.clinthera.2010.11.006_bib2","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","article-title":"Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology","volume":"162","author":"McDougle","year":"2005","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.clinthera.2010.11.006_bib3","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0090-9556(25)08211-X","article-title":"Absorption, metabolism, and excretion of risperidone in humans","volume":"21","author":"Mannens","year":"1993","journal-title":"DrugMetab Dispos."},{"key":"10.1016\/j.clinthera.2010.11.006_bib4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/clpt.1993.146","article-title":"Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects","volume":"54","author":"Huang","year":"1993","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2010.11.006_bib5","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.clinthera.2007.07.026","article-title":"Plasma pharmacokinetic characteristics of risperidone and their relation- ship to saliva concentrations in children with psychiatric or neurodevelopmental disorders","volume":"29","author":"Aman","year":"2007","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2010.11.006_bib6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0022-3565(25)13416-2","article-title":"Biochemical profile of risperidone, a new antipsychotic","volume":"247","author":"Leysen","year":"1988","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.clinthera.2010.11.006_bib7","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jpba.2005.10.034","article-title":"Structural studies of impurities of risperidone by hyphenated techniques","volume":"40","author":"Sattanathan","year":"2006","journal-title":"J Pharm Biomed Anal."},{"key":"10.1016\/j.clinthera.2010.11.006_bib8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1570-0232(02)00661-X","article-title":"Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: Application to the evaluation of CYP2D6 drug interactions","volume":"783","author":"Llerena","year":"2003","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"10.1016\/j.clinthera.2010.11.006_bib9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1570-0232(02)00715-8","article-title":"Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry","volume":"783","author":"Remmerie","year":"2003","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"10.1016\/j.clinthera.2010.11.006_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0378-4347(00)00323-6","article-title":"Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection","volume":"746","author":"Avenoso","year":"2000","journal-title":"J Chromatogr B Biomed Sci Appl."},{"key":"10.1016\/j.clinthera.2010.11.006_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF02246543","article-title":"Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man","volume":"122","author":"Snoeck","year":"1995","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.clinthera.2010.11.006_bib12","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s002130051171","article-title":"Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone","volume":"147","author":"Scordo","year":"1999","journal-title":"Psychopharmacology (Berl)."},{"journal-title":"Di\u00e1rio Oficial da Rep\u00fablica Federativa do Brasil","first-page":"8269","year":"1993","key":"10.1016\/j.clinthera.2010.11.006_bib13"},{"key":"10.1016\/j.clinthera.2010.11.006_bib14","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1590\/S0102-311X2009001000006","article-title":"Disponibilidade no setor p\u00fablico e pre\u00e7os no setor privado: Um perfil de medicamentos gen\u00e9ricos em diferentes regi\u00f5es do Brasil","volume":"25","author":"Miranda","year":"2009","journal-title":"Cad Saude Publica."},{"year":"2006","series-title":"Resolu\u00e7\u00e3o RE n.1170. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria\u2014. Guia para provas de biodisponibilidade e bioequival\u00eancia de medicamentos","key":"10.1016\/j.clinthera.2010.11.006_bib15"},{"year":"2002","series-title":"Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products\u2014General Considerations","key":"10.1016\/j.clinthera.2010.11.006_bib16"},{"key":"10.1016\/j.clinthera.2010.11.006_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods."},{"year":"2008","series-title":"World Medical Asso- ciation-Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 59th WMA General Assembly","key":"10.1016\/j.clinthera.2010.11.006_bib18"},{"key":"10.1016\/j.clinthera.2010.11.006_bib20_1","series-title":"A cl\u00ednica e o laborat\u00f3rio","first-page":"159","author":"Gorina","year":"1996"},{"key":"10.1016\/j.clinthera.2010.11.006_bib20_2","series-title":"A cl\u00ednica e o laborat\u00f3rio","first-page":"527","author":"Gorina","year":"1996"},{"year":"2007","series-title":"Compara\u00e7\u00e3o entre a contagem de plaquetas pelos m\u00e9todos manual e automatizado","author":"Leite","key":"10.1016\/j.clinthera.2010.11.006_bib21"},{"key":"10.1016\/j.clinthera.2010.11.006_bib22_1","series-title":"M\u00e9todos de laborat\u00f3rio aplicados a clinica. T\u00e9cnica e Interpreta\u00e7\u00e3o","first-page":"2","author":"Lima","year":"1992"},{"key":"10.1016\/j.clinthera.2010.11.006_bib22_2","series-title":"M\u00e9todos de laborat\u00f3rio aplicados a clinica. T\u00e9cnica e Interpreta\u00e7\u00e3o","first-page":"21","author":"Lima","year":"1992"},{"key":"10.1016\/j.clinthera.2010.11.006_bib23_1","series-title":"Manual de t\u00e9cnicas hematol\u00f3gicas","first-page":"193","author":"Vallada","year":"1996"},{"key":"10.1016\/j.clinthera.2010.11.006_bib23_2","series-title":"Manual de t\u00e9cnicas hematol\u00f3gicas","first-page":"239","author":"Vallada","year":"1996"},{"year":"2000","series-title":"Design and Analysis of Bioavailability and Bioequivalence Studies","author":"Chow","key":"10.1016\/j.clinthera.2010.11.006_bib24"},{"year":"2004","series-title":"Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish inter-changeability","key":"10.1016\/j.clinthera.2010.11.006_bib25"},{"key":"10.1016\/j.clinthera.2010.11.006_bib26","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5414\/CPP47124","article-title":"Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers","volume":"47","author":"Canovas","year":"2009","journal-title":"Int J Clin Pharmacol Ther."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810003681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810003681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T09:04:36Z","timestamp":1740733476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291810003681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0149291810003681"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.11.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}